IOVANCE BIOTHERAPEUTICS, INC. Amortization of Intangible Assets
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Amortization of Intangible Assets of $11.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-06
- IOVANCE BIOTHERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2026-06-30 was $5.72M, a 0.28% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2026-03-31 was $5.72M, a 4.02% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2025-12-31 was $6.20M, a 42.14% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. amortization of intangible assets for the quarter ending 2025-09-30 was $5.80M, a 5.45% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. amortization of intangible assets for fiscal 2025 was $23.08M, a 12.52% decline from fiscal 2024.
- IOVANCE BIOTHERAPEUTICS, INC. amortization of intangible assets for fiscal 2024 was $26.38M, a 167.83% increase from fiscal 2023.
- IOVANCE BIOTHERAPEUTICS, INC. amortization of intangible assets for fiscal 2023 was $9.85M.
- IOVANCE BIOTHERAPEUTICS, INC. amortization of intangible assets for fiscal 2022 was $0.00.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $11.43M 10-Q · filed 2026-08-06 | $17.64M derived: sum of 3 quarters · filed 2026-08-06 | $23.44M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $5.72M 10-Q · filed 2026-05-07 | $11.92M derived: sum of 2 quarters · filed 2026-05-07 | $17.72M derived: sum of 3 quarters · filed 2026-05-07 | $23.42M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2025-12-31 | $6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $12.00M derived: sum of 2 quarters · filed 2026-02-24 | $17.70M derived: sum of 3 quarters · filed 2026-02-24 | $23.08M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $5.80M 10-Q · filed 2025-11-06 | $11.50M derived: sum of 2 quarters · filed 2025-11-06 | $16.87M 10-Q · filed 2025-11-06 | $27.72M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2025-06-30 | $5.70M 10-Q · filed 2025-08-07 | $11.46M 10-Q · filed 2026-08-06 | $11.10M 10-Q · filed 2025-08-07 | $21.92M derived: sum of 3 quarters · filed 2026-05-07 | $27.42M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2025-03-31 | $5.50M 10-Q · filed 2026-05-07 | $5.41M 10-Q · filed 2025-05-08 | $16.22M derived: sum of 2 quarters · filed 2026-05-07 | $21.72M derived: sum of 3 quarters · filed 2026-05-07 | $27.22M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $10.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $16.22M derived: sum of 2 quarters · filed 2026-02-24 | $21.72M derived: sum of 3 quarters · filed 2026-02-24 | $26.38M 10-K · filed 2026-02-24 | $21.20M 10-K · filed 2025-02-27 | ||
| 2024-09-30 | $5.50M 10-Q · filed 2025-11-06 | $11.00M derived: sum of 2 quarters · filed 2025-11-06 | $15.66M 10-Q · filed 2025-11-06 | $19.54M derived: sum of 4 quarters · filed 2026-02-24 | |||
| 2024-06-30 | $5.50M 10-Q · filed 2025-08-07 | $10.12M 10-Q · filed 2025-08-07 | $14.04M derived: sum of 3 quarters · filed 2026-02-24 | $18.04M derived: sum of 4 quarters · filed 2026-02-24 | |||
| 2024-03-31 | $4.63M 10-Q · filed 2025-05-08 | $8.54M derived: sum of 2 quarters · filed 2026-02-24 | $12.54M derived: sum of 3 quarters · filed 2026-02-24 | $14.44M derived: sum of 4 quarters · filed 2026-02-24 | |||
| 2023-12-31 | $3.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $7.91M derived: sum of 2 quarters · filed 2026-02-24 | $9.81M derived: sum of 3 quarters · filed 2026-02-24 | $9.85M 10-K · filed 2026-02-24 | |||
| 2023-09-30 | $4.00M 10-Q · filed 2024-11-07 | $5.90M derived: sum of 2 quarters · filed 2024-11-07 | $5.94M 10-Q · filed 2024-11-07 | $5.90M derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2023-06-30 | $1.90M 10-Q · filed 2024-08-08 | $1.93M 10-Q · filed 2024-08-08 | $1.90M derived: sum of 3 quarters · filed 2024-08-08 | $1.90M derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-05-09 | $0.00 derived: sum of 3 quarters · filed 2024-05-09 | $0.00 derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $0.00 derived: sum of 3 quarters · filed 2024-02-28 | $0.00 10-K · filed 2024-02-28 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | ||||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |